Inventiva Reveals Promising Phase 2 Study Results of Lanifibranor and Empagliflozin Combination

Inventiva has announced it will present final data from its Phase 2 study, LEGEND, evaluating the combination of lanifibranor and empagliflozin in patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Type 2 Diabetes (T2D). The presentation will occur at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® in San Diego on November 18, 2024.

The study showed both the lanifibranor monotherapy and its combination with empagliflozin substantially reduced HbA1c levels compared to placebo, with 50% of patients achieving levels under 6.5% by week 24. Additionally, significant improvement was noted in several cardiometabolic parameters, and concerns regarding weight gain with lanifibranor alone were addressed by the addition of empagliflozin.